Two years ago, 10-year-old Bo Bratschie experienced weight loss and high fevers, leading to many hospital visits before being diagnosed with Crohn’s disease at ...

Horsham: Johnson & Johnson is seeking the U.S. Food and Drug Administration (FDA) approval for the expansion of STELARA ...

In children with UC, biologic therapy may prove to be more efficacious ... in up to 34% of patients at 5 years from diagnosis. Ulcerative colitis in children is often characterized by extensive ...

For children with severe Crohn disease, upadacitinib offers an effective induction therapy, but its benefits must be carefully weighed against potential adverse events.

Johnson & Johnson submitted a supplemental Biologics License Application to expand Stelara’s use to children aged two years ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Such agents, called 'biological agents' or simply 'biologicals', are revolutionizing the treatment of IBD in Western countries. Although not readily accessible, these agents will eventually become ...

ABOUT 5.7 MILLION men could have an autoimmune disease, according to a 2024 study published in the Journal of Clinical ...

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Patients with inflammatory bowel disease (IBD) show high acceptance of adalimumab biosimilars, achieving positive outcomes and clinical remission after switching.